tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Phase 2 Terminated 7 enrolled Luca Cardone Anticancer Fund, Belgium · collab Azienda Ospedaliera Universitaria Integrata Verona · collab Catholic University of the Sacred Heart · collab Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale · collab San Raffaele University Hospital, Italy · collab University of Pisa · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is designed to assess the therapeutic efficacy of decitabine repurposing against advanced, refractory, ductal adenocarcinoma (PDAC) with molecular transcriptional signatures indicating dependency on the KRAS oncogene

Timeline

Start: 2022-01-15
Primary completion: 2024-10-10
Completion: 2024-10-10

Outcome

Outcome not reported

Stopped: “Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.”

Publications

Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibanez-Costa A, Dubrot J, Earl J, Melian EB, Kataki A, Kolnikova G, Madjarov G, Chaushevska M, Strnadel J, Tanic M, Tomas M, Dubovan P, Urbanova M, Buocikova V, Smolkova B. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025 Feb;109:101-124. doi: 10.1016/j.semcancer.2025.01.003. Epub 2025 Jan 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	10 mg/m2	Intravenous